Health Blog

Tips | Recommendations | Reviews

Who Owns Definitive Healthcare?

Who Owns Definitive Healthcare
From Wikipedia, the free encyclopedia

Advent International Corporation

Headquarters at Prudential Tower
Type Private
Industry Private Equity
Founded 1984 ; 39 years ago
Founder Peter Brooke
Headquarters Boston, Massachusetts, United States
Products Private equity funds, buyouts
AUM $89 billion (2022)
Number of employees 475+
Website adventinternational,com

Advent International is a global private equity firm focused on buyouts of companies in Western and Central Europe, North America, Latin America and Asia, The firm focuses on international buyouts, growth and strategic restructuring in five core sectors.

Who bought definitive healthcare?

22C Capital Announces Investment in Definitive Healthcare – October 2, 2019 – 22C Capital (“22C”) announced today that it has made an investment in Definitive Healthcare (“the Company”), a leading data and analytics provider across the healthcare ecosystem.22C was invited by Founder and CEO Jason Krantz, Advent International (“Advent) and Spectrum Equity (“Spectrum”), to join in the Company’s most recent recapitalization that was announced in June 2019.

  1. Financial terms were not disclosed.22C is a private investment firm with an established track record of working with other private equity firms and founder-led companies to help them scale in key functional areas such as data, technology, and commercialization.
  2. We are very pleased to partner with Advent and Spectrum to help Jason and his management team realize the exciting vision he has set out for the Company,” said Randall Winn, Managing Partner of 22C.

” Definitive Healthcare is currently in a phase of hypergrowth and 22C is well positioned to help with key operational initiatives that rely on scaling data collection, technology, product innovation, and commercial efforts, all areas where 22C has deep expertise,” Advent Principal Lauren Young added, ” We are thrilled to partner with 22C who brings a unique value creation approach given their strong operational and investing backgrounds in enterprise data businesses.

  • Definitive Healthcare will greatly benefit from their deep expertise and collaborative approach with management teams and private equity funds as it continues to scale and experience incredible growth.
  • It is apparent that 22C brings a differentiated skill set that is highly complementary to our existing investor group and management team, ” said Jason Krantz.

” In advance of their investment, 22C rolled up their sleeves and helped us in key areas related to technology and product development as well as made multiple strategic introductions,” Founded in 2011 by Jason Krantz, Definitive Healthcare is the leading data-as-a-service provider to the U.S.

healthcare industry, helping its clients size market opportunities, support strategic decision-making and drive sales and marketing. Among Definitive Healthcare’s 2,200+ clients are some of the world’s largest pharmaceutical and medical device companies, top healthcare technology companies, cutting-edge healthcare start-ups and the most forward-thinking healthcare providers.

The Company operates throughout the U.S. and is based in Framingham, MA. ” Jason has built a very unique platform in the healthcare space “, added Eric Edell, Managing Partner at 22C Capital. ” The Company’s integrated and proprietary data model is the foundation for a commercial platform that provides highly actionable and must-have insights and analytics for all players in the healthcare ecosystem,” Jeff Haywood, Managing Director at Spectrum, added, ” Since partnering with Jason and the Company in 2015, we’ve seen firsthand the Company’s tremendous growth, commitment to customer success and market leadership.

We look forward to working with the teams at Advent and 22C in this next growth phase for the Company,” About Definitive Healthcare Definitive Healthcare is the leading provider of data and intelligence on hospitals, physicians and other healthcare providers. Its product suite provides the most comprehensive and highest quality data available anywhere on 8,800 hospitals and IDNs; 148,000 physician groups; 1.7 million physicians, nurses, and allied health professionals; 11,200 ambulatory surgery centers; 14,600 imaging centers; 91,600 long-term care facilities; 40,000 clinics; 1,400 ACOs and HIEs; more than 4 billion commercial medical and Rx claims; 115,000 clinical trials; and 900 Canadian hospitals.

The company’s data provides its 2,200+ clients with the analytics and insight needed to effectively segment and research the healthcare provider market. For more information, or to trial the service, visit https://www.definitivehc.com /. About 22C Capital 22C Capital is a private investment firm committed to delivering capital and critical resources to companies operating at the intersection of technology enablement and data analytics adoption.

  • The firm has a dedicated focus on the business services, healthcare, and financial services sectors.22C partners with world-class management teams to build companies that are leaders in their respective markets.
  • The firm’s operational and technology resources, including its affiliated data science organization, deliver practical, real-world support to help convert businesses’ challenges into opportunities and unlock their full potential.

For more information, visit: http://www.22ccapital.com/ About Advent International Founded in 1984, Advent International is one of the largest and most experienced global private equity investors. The firm has invested in over 345 private equity transactions in 41 countries, and as of June 30, 2019, had $54.3 billion in assets under management.

With 15 offices in 12 countries, Advent has established a globally integrated team of over 195 investment professionals across North America, Europe, Latin America and Asia. The firm focuses on investments in five core sectors, including business and financial services; healthcare; industrial; retail, consumer and leisure; and technology.

After 35 years dedicated to international investing, Advent remains committed to partnering with management teams to deliver sustained revenue and earnings growth for its portfolio companies. For more information, visit Website: www.adventinternational.com LinkedIn: www.linkedin.com/company/advent-international About Spectrum Equity Spectrum Equity is a leading growth equity firm providing capital and strategic support to innovative companies in the information economy.

  • For over 25 years, the firm has partnered with proven entrepreneurs and management teams to build long-term value in market-leading software, information services and internet companies.
  • Representative investments include Ancestry, Bats Global Markets, GoodRx, Grubhub, Lynda.com, Net Health, RainKing, SurveyMonkey and Verafin.

For more information, including a complete list of portfolio investments, visit www.spectrumequity.com, ###

Did definitive healthcare go public?

Business: (Note: Definitive Healthcare Corp. priced its IPO on Sept.14, 2021, at $27 – above the top of its $24-to-$26 price range – and priced 15.56 million – to raise $420.12 million. In an S-1/A filing dated Sept.13, 2021, Definitive Healthcare had raised its price range to $24 to $26 – up from $21 to $24 initially – and kept the number of shares at 15.56 million.) Our mission is to make the complex healthcare ecosystem easier to analyze, navigate and sell into by providing a comprehensive, cloud-based healthcare commercial intelligence platform.

Definitive Healthcare is a leading provider of healthcare commercial intelligence. Our solutions provide accurate and comprehensive information on healthcare providers and their activities to help our customers optimize everything from product development to go-to-market planning and sales and marketing execution.

Delivered through our software as a service (“SaaS”) platform, our intelligence has become critical to the commercial success of our over 2,600 customers as of June 30, 2021. Commercial success within the healthcare ecosystem is difficult to achieve. The complex relationships between physicians, hospitals, providers, healthcare insurance companies, government regulators and patients make it particularly difficult to develop products for and sell products into the healthcare ecosystem.

See also:  Why Is Interprofessional Collaboration Important In Healthcare?

To succeed in the industry, companies benefit from deep healthcare commercial intelligence that maps all the major players in the healthcare ecosystem, knowledge of the affiliations and relationships between the industry participants and an ability to size patient populations by disease area, geography and health system.

Companies that compete within or sell into this ecosystem can utilize the Definitive Healthcare platform to navigate these complexities, enhance go-to-market strategies and access the provider and decision maker information needed to succeed. Our customers include biopharmaceutical and medical device (“Life Sciences”) companies, Healthcare Information Technology (“HCIT”) companies, healthcare providers and other diversified companies, such as staffing firms, commercial real estate firms, financial institutions and other organizations seeking commercial success in the attractive but complex healthcare ecosystem.

  1. Within these organizations, our platform is leveraged by a broad set of functional groups, including Sales, Marketing, Clinical Research & Product Development, Strategy, Talent Acquisition and Physician Network Management.
  2. Address 550 Cochituate Rd Framingham, MA 01701 Net Income $-51.4 mil (last 12 months) Manager / Joint Managers Goldman Sachs/J.P.

Morgan/Morgan Stanley/Barclays/Credit Suisse/Deutsche Bank Securities

Who is the CEO of definitive healthcare?

Robert Musslewhite is the Chief Executive Officer of Definitive Healthcare and has served as a member of the board of directors of the Company since June 2021.

Should I buy definitive healthcare stock?

Definitive Healthcare has received a consensus rating of Hold. The company’s average rating score is 2.43, and is based on 3 buy ratings, 4 hold ratings, and no sell ratings.

What is the largest healthcare SPAC?

MultiPlan. Healthcare insurance data analytics firm MultiPlan merged with Churchill Capital Corp III in a deal worth about $11 billion, making it one of the largest U.S. SPAC deals ever—at the time, at least.

What is the IPO price of definitive healthcare?

Definitive Healthcare is registered under the ticker NASDAQ:DH. Their stock opened with $27.00 in its Sep 15, 2021 IPO.

Who are Medtronic’s largest competitors?

Medtronic main competitors are Intuitive Surgical, Edwards Lifesciences, and Genentech. Competitor Summary, See how Medtronic compares to its main competitors:

Johnson & Johnson has the most employees (134,500).Employees at Intuitive Surgical earn more than most of the competitors, with an average yearly salary of $113,813.The oldest company is Bausch + Lomb, founded in 1853.

Who is the CEO of Elephant Health?

Chen Yuanfei is the Co-Founder & CEO at Elephant Medical.

Who is the director of Slaney healthcare?

You are here – Home › Slaney Healthcare Private Limited Slaney Healthcare Private Limited is a Private incorporated on 16 January 2008. It is classified as Non-govt company and is registered at Registrar of Companies, Ahmedabad. Its authorized share capital is Rs.500,000 and its paid up capital is Rs.100,000.

It is inolved in Manufacture of medical appliances and instruments and appliances for measuring, checking, testing, navigating and other purposes except optical instruments Slaney Healthcare Private Limited’s Annual General Meeting (AGM) was last held on 24 September 2022 and as per records from Ministry of Corporate Affairs (MCA), its balance sheet was last filed on 31 March 2022.

Directors of Slaney Healthcare Private Limited are Darshini Vikram Shah, Viral Bhalchandra Shah, Ravi Bhandari, Shanay Vikram Shah,, Slaney Healthcare Private Limited’s Corporate Identification Number is (CIN) U33125GJ2008PTC052648 and its registration number is 52648.Its Email address is [email protected] and its registered address is Shalby Multi-Specialty Hospitals, Opp.

What is definitive healthcare target price?

Stock Price Forecast – The 12 analysts offering 12-month price forecasts for Definitive Healthcare Corp have a median target of 14.00, with a high estimate of 17.00 and a low estimate of 10.00. The median estimate represents a +37.39% increase from the last price of 10.19.

Who is the king of SPAC?

Tech startups hopelessly addicted to Silicon Valley’s drug of choice face a reckoning now that they’ve been forced to quit cold turkey. Already a subscriber? Sign in

All of our iconic lists and rankings, including the Fortune 500 Full access to our market-moving business journalism Exclusive quarterly investment guides

Renews monthly after trial Billed annually at $95.40 Renews at $227.40 Cancel anytime Billed annually at $131.40 Renews at $263.40 Cancel anytime

Learn more about the subscription offers. The end of the Federal Reserve’s zero-interest-rate policy, or ZIRP, represents a “generation-defining economic regime change” for a sector hooked on cheap, plentiful money, according to billionaire venture capitalist Chamath Palihapitiya.

Loss-making firms must now either sober up, get control of their costs, and stop burning cash or they won’t be around to profit from the $2-trillion-plus tsunami of government spending launched under President Joe Biden. “The era of excess, abundance, and zero-interest-rate policy has come to an end,” wrote Palihapitiya in his annual letter to Social Capital’s limited partners published on Tuesday.

“Last year, we likened it to ending the best party in town—but instead of simply turning on the lights, the past year has been more akin to getting cold water thrown in our faces.” That means founders will have to deliver tangible bottom-line earnings both before and, more important, after accounting for running costs of line items like interest, taxes, depreciation, and amortization.

Who owns SPAC?

How special purpose acquisition companies (SPACs) work Special purpose acquisition companies (SPACs) have become a preferred way for many experienced management teams and sponsors to take companies public. A SPAC raises capital through an initial public offering (IPO) for the purpose of acquiring an existing operating company.

  1. Subsequently, an operating company can merge with (or be acquired by) the publicly traded SPAC and become a listed company in lieu of executing its own,
  2. A recent PwC Deals blog explores, including recent trends and the potential advantages.
  3. Here we discuss how SPAC mergers work and the related accounting and reporting issues.

This approach offers several distinct advantages over a traditional IPO, such as providing companies access to capital, even when market volatility and other conditions limit liquidity. SPACs could also potentially lower transaction fees as well as expedite the timeline to become a public company. Generally, a SPAC is formed by an experienced management team or a sponsor with nominal invested capital, typically translating into a ~20% interest in the SPAC (commonly known as founder shares). The remaining ~80% interest is held by public shareholders through “units” offered in an IPO of the SPAC’s shares.

Who are the top investors in SPAC?

As SPAC Bubble Burst, Hedge Funds Doubled Their Holdings The SPAC bubble burst last year, resulting in hedge funds holding $170.5 billion worth of special purpose acquisition companies — more than double what they owned at the end of 2020. Hedge funds, nicknamed the “SPAC Mafia” because they are the dominant buyer of SPAC IPO shares and warrants, owned only $82.4 billion at the end of 2020, according to SPAC Research, a data provider.

See also:  How To Value A Healthcare Company?

The current glut of SPACs is, in part, due to the difficulty these blank-check companies have had in hooking up with merger partners. Almost 800 SPACs filed for IPOs last year, raising $162.5 billion — more than half of the $300 billion raised since the financial crisis of 2008, SPAC Insider reports.

But last year only 71 merger deals were announced, and just 53 completed. As the mania subsided, retail investors fled and SPACs fell back to their IPO price of $10 — or slightly below that — per share, prompting more hedge fund arb players to move into the market.

  1. Before a merger is finalized, SPAC owners are guaranteed their net asset value, typically $10 per share, if they redeem at that time.
  2. That’s also the case even if the SPAC ends up in liquidation, and many observers expect liquidations to increase as SPACs reach the two-year time limit they have to find a merger partner.

Marshall Wace is among those that bulked up on SPACs during the year. The London-based hedge fund is now the top SPAC owner among hedge funds, holding almost $5.28 billion — up from less than $1 billion at the end of 2020, according to SPAC Research. It bought almost $1 billion of SPACs during the fourth quarter.

Its biggest holdings include SPACs sponsored by private equity firms Apollo, KKR, and Fortress, as well as the latest offered by former Citi banker Michael Klein (Churchill Capital VII), former Goldman Sachs CEO Gary Cohen, and Bill Ackman’s Pershing Square Tontine Holdings. Another big SPAC gainer among hedge funds is SABA Capital Management, which became the fourth-biggest SPAC hedge fund investor at the end of 2021.

SABA bought $2 billion worth during the quarter to end the year with $4.26 billion in SPACs. At the end of 2020, it only owned SPACs worth about $81 million. Millennium Management, which had been the top hedge fund SPAC investor for most of 2021, fell to second place, with $4.89 billion, an increase of only about $400 million during the year.

  • Citadel ranked third, with $4.31 billion, up from $1.37 billion at the end of 2020.
  • Meanwhile, Glazer Capital — which had been one of the top three players last year — sold almost $2 billion worth during the last six months of 2021.
  • Glazer ended 2021 with a little under $3 billion in SPACs, compared with $4.82 billion at the end of June.

It fell to eleventh place in the SPAC ownership ranking. Other top SPAC-owning hedge funds at yearend include D.E. Shaw, with $4.25 billion; Magnetar Financial, with $4.25 billion; Aristeia Capital, with $3.78 billion; Periscope Capital, with $3.59 billion; Radcliffe Capital, with $3.04 billion; and Sculptor Capital, with $3 billion.

Who bought definitive technology?

We still design and engineer our speakers at our original Acoustic Research and Development (ARAD) facility in Owings Mills, Maryland, but today we’re part of a larger family: Masimo Consumer.

Who bought Artemis Health?

Nomi Health Acquires Artemis Health to Accelerate Transformation of U.S. Healthcare with Actionable Insights The acquisition advances Nomi Health’s growth and impact by delivering the actionable data buyers of healthcare need to lower costs and improve care Orem, UT – January 6, 2022 -, the leading direct healthcare provider in America, today announced its acquisition of healthcare analytics provider Artemis Health – the partner of choice for more than 500 U.S.

Employers and benefits advisors to make health benefits higher quality and more affordable using data. The transaction gives Nomi Health customers actionable, data-driven insights to materially lower costs and improve the quality of care they deliver to their communities. The acquisition will also accelerate the growth of Nomi Health’s platform and services, which has already delivered higher quality care at lower costs for major buyers of healthcare in more than 15 states.

“We launched in 2019 as a modern platform that enables U.S. healthcare to run better, faster and more cost effectively than the status quo for buyers of healthcare, for providers and for all of us as patients. Since then, we’ve helped our public and private sector customers cut the cost of care by 30 percent while improving access to care for over 10 million Americans.

Artemis will play a key role in how the next phase of our platform comes to life,” said Mark Newman, founder and CEO of Nomi Health. “As costs skyrocket and access shrinks, organizations need clear data at their fingertips and partners who know how to turn these insights into action. Our acquisition of Artemis Health does exactly that.

Artemis shares Nomi’s outlook that U.S. healthcare is fundamentally broken and new market entrants are best positioned to rebuild it. Artemis’ leadership is well respected, its modern solutions are well designed, and its customers and partners are actively invested in a better way forward.

  1. We’re eager to bring Artemis solutions to the nation’s governors, mayors, CEOs and leaders who are now in the driver’s seat of change more than ever because of the pandemic.
  2. Together with Artemis, we will accelerate our roadmap to transform U.S.
  3. Healthcare for good.” The Artemis Health acquisition immediately bolsters the company’s Nomi Connect platform, a business operating system and payment rails that directly connects providers to buyers.

Based in Salt Lake City, Artemis Health is the go-to partner for more than 500 employers, benefits advisors and health plans, including Intuit, US Foods, Paychex, GE Appliances, and J.B. Hunt. With more than 10 million lives on its platform, Artemis’ analytics solutions deliver powerful tools and insights that help employers provide high-quality benefits to their members while managing rising care costs.

  • Their team of 120 will join the Nomi Health team of more than 2,000 while continuing to support their customers with seamless integration.
  • Nomi Health shares our passion to improve the cost and quality of healthcare in the US,” said Grant Gordon, Co-founder and CEO of Artemis Health.
  • We are excited to bring our best-in-class data analytics capabilities to Nomi’s customers and work together to close the gap between insight and action in healthcare.

Together we will continue to accelerate Artemis’ development of innovative analytics solutions for employers and their advisors, and further our mission by expanding our impact.” The acquisition of Artemis Health comes on the heels of Nomi Health’s $110 million Series A, co-led by Rose Park Advisors and Arbor Ventures.

  1. Last year, Nomi Health also became the largest corporate donor to RIP Medical Debt, across more than 175,000 Americans.
  2. To learn more about Nomi Health, visit,
  3. About Nomi Health Nomi Health is a direct healthcare company successfully re-wiring how healthcare is bought, paid for and delivered in America, to the benefit of patients, providers and the buyers of healthcare in both the public and private sectors.
See also:  How Does Cost Affect Quality In Healthcare?

Based in Orem, Utah, we’re a team of over 2,000 nationwide, each actively working to lower care costs, widen care access and improve the experience for all. The company’s Nomi Care platform – featuring local clinical and operations field teams, a sustainable supply chain, and seven networked laboratories – have served over ten million Americans with everyday healthcare services.

Nomi Connect is a business operating system and payment platform enabling organizations to purchase healthcare directly and providers to be paid in real time. Nomi Health’s cross-functional leadership team hails from America’s most established clinical, healthcare, technology and finance organizations.

Visit us @NomiHealth and, ‍ : Nomi Health Acquires Artemis Health to Accelerate Transformation of U.S. Healthcare with Actionable Insights

When did definitive healthcare acquire monocl?

Company Adds Broad Expert Data to its Life Sciences Offering to Help Clients Advance Clinical Development and Commercialization of Innovative Drugs and Therapies – FRAMINGHAM, MA – October 29, 2020 – Definitive Healthcare, the leading provider of data, intelligence, and analytics on the healthcare market, today announced its acquisition of Monocl, the pre-eminent subscription-based provider of medical and scientific expert data and insights.

With this acquisition, Definitive Healthcare broadens its support of customers within its fast-growing life sciences segment with essential data assets and analytics designed to propel the work of Medical Affairs departments, ” The acquisition of Monocl brings together two powerful intelligence platforms to provide best-in-class data, analytics and insight that will help biotech and pharmaceutical companies accelerate clinical research and commercialization of new drugs and therapies,” said Jason Krantz, founder and CEO of Definitive Healthcare.

” Monocl shares the Definitive philosophy of providing the highest quality data through an online interface that gives clients the ability to access and analyze real-time information and intelligence,” Monocl delivers deep professional profiles on millions of experts worldwide to help companies identify and engage industry experts with the greatest knowledge, influence, and relevancy within the disease categories their drugs and therapies address.

Traditionally, this data has been time-consuming to identify, inefficient, and incomplete, but the Monocl platform has transformed identification and engagement by providing users with real-time access and searching for experts globally. ” Monocl further fortifies our team with experienced industry veterans and with a strong life sciences and healthcare network,” Krantz added.

” Our combined offering will expand the value of the Definitive solution set by enabling our clients to research and engage prominent experts to advance drug and therapy research and go-to-market strategies,” Through deep expert profiles and high data quality, targeted searching, and powerful filtering, the Monocl platform delivers algorithmically ranked experts of unmatched relevance to the user.

Pharmaceutical professionals have the flexibility to identify and prioritize key influencers to support their specific objectives, evaluate spheres of influence, and share deep insights via digital workspaces for multi-team collaboration. ” Monocl has always been laser focused on delivering critical expert insights through software to provide our clients with a unique competitive and collaborative edge,” said Bjorn Carlsson, CEO and co-founder of Monocl.

” We are thrilled to unite the power of our groundbreaking expert platform with Definitive’s comprehensive and complementary healthcare provider platform and medical claims analytics. This is truly an example of the whole being much greater than the sum of its parts,” With this acquisition, Definitive Healthcare fortifies its product offerings for life sciences companies by delivering relevant data sets and analytics to both commercial teams and Medical Affairs departments.

In addition, Definitive expands its international presence from North America to Europe and Asia. In 2020, Definitive Healthcare was, again, named to the Inc.5000 Fastest-Growing Private Companies and to the Boston Business Journal’s Fast 50. The Company was also recognized with the 2020 CODiE product award for Best Big Data Reporting and Analytics Solution and with the 2020 MedTech Breakthrough award for Best Healthcare Data Platform.

For the second consecutive year, Definitive Healthcare was awarded a Silver Stevie Award for industry-leading Customer Service and Satisfaction. Definitive was also named Massachusetts’ #1 Best Large Company to Work for in 2019 by the Boston Business Journal.

” It was really important for us to join forces with a partner that shares our commitment to customers and to providing products enabling the best insights possible. We could not have found a better match, and our entire team is thrilled to be joining the Definitive family,” said Carlsson. Monocl will continue to serve its worldwide customer base under its current brand, as a Definitive Healthcare Company, and will maintain its existing operations in the US and Sweden.

Bjorn Carlsson will be a member of Definitive Healthcare’s executive leadership team. About Definitive Healthcare Definitive Healthcare is the most comprehensive and accurate source for data insights and analytics on the healthcare provider and influencer market.

Its product suite provides the most comprehensive and highest quality data available anywhere on 8,800 hospitals and IDNs; 135,000 physician groups; 1.7 million physicians, nurses, and allied health professionals; 11,000 ambulatory surgery centers; 15,800 imaging centers; 85,500 long-term care facilities; 40,000 clinics; 1,800 ACOs and HIEs; 5.7 billion medical commercial claims covering 315 million patient lives, and insights on millions of Key Opinion Leaders in life sciences and healthcare.

The company’s data provides its 2,500 clients with the analytics and insight needed to effectively segment and research the healthcare provider market. Definitive Healthcare is backed by 22C Capital, Advent International, and Spectrum Equity. For more information, or to trial the service, visit https://www.definitivehc.com/,

  • About Monocl Monocl empowers life science professionals with the complete global expert solution designed to drive impactful outreach and strategic engagement.
  • Our cloud-based expert platform – powered by machine learning – continuously analyzes an unrivaled amount of data across all therapeutic areas and regions, providing invaluable context and actionable insights.

For more information, including details on how to get product access, visit https://www.monocl.com/, Media Contact Tory Waldron PR Manager [email protected] (781) 454-6822 ###

What is the IPO price of definitive healthcare?

Definitive Healthcare is registered under the ticker NASDAQ:DH. Their stock opened with $27.00 in its Sep 15, 2021 IPO.

Adblock
detector